VIVESTO AB Uppsala,
- XMeNa patent approved in
India and soon inAustralia . - Registrations for Apealea approved in
Switzerland ,Israel ,South Africa ,Malaysia andIndonesia during 2020.
The XMeNa platform patent approved in further important markets
The XMeNa patent protects an improved method for producing Oasmia’s nanotechnology platform XR-17™, which is a unique carrier system for anticancer drugs. The patent is crucial for Oasmia as it increases the exclusivity for the key technology XR‑17 and our lead product Apealea® (paclitaxel micellar), which is being lauched in key markets globally.
The XMeNa patent is already approved in several major pharmaceutical markets, such as the US. Approval is furthermore pending in several other major markets around the world, such as
The patent was approved in
The trademark portfolio for Apealea® continues to grow – update on current registrations
Owning a distinguishable brand and trademark is an important part of establishing market and patient awareness at Oasmia. The Apealea trademark helps to build the long-term brand to enable increased sales and customer loyalty.
Apealea is a registered and protected trademark in the EU and the US. In 2020, additional registrations were approved for Apealea in
For more information:
Phone: +46 18-50 54 40
E-mail: IR@oasmia.com
Phone: +44 (0)20 3709 5700
E-mail: oasmia@consilium-comms.com
About
Oasmia is a specialty pharma company dedicated to improving the lives of patients by enhancing the intravenous delivery of established and novel drugs in significant diseases, including cancer. Product development is based on the Company’s proprietary drug delivery technology platform XR-17™ which can be applied to medicines used in many therapeutic areas, to develop water soluble formulations of drugs that currently require chemical solubilizers for dissolution. The first product approved using this technology is Apealea® (paclitaxel micellar). Apealea has received market authorization in the
© Modular Finance, source
